Intervention Protocol

Levamisole for chronic hepatitis B

  1. Kate Whitfield1,*,
  2. Lina Saem Stoey2,
  3. Maria Skoog2,
  4. Jane Lindschou Hansen2,
  5. Khalid Mumtaz3,
  6. Christian Gluud4

Editorial Group: Cochrane Hepato-Biliary Group

Published Online: 10 NOV 2010

Assessed as up-to-date: 30 AUG 2010

DOI: 10.1002/14651858.CD008845


How to Cite

Whitfield K, Stoey LS, Skoog M, Lindschou Hansen J, Mumtaz K, Gluud C. Levamisole for chronic hepatitis B (Protocol). Cochrane Database of Systematic Reviews 2010, Issue 11. Art. No.: CD008845. DOI: 10.1002/14651858.CD008845.

Author Information

  1. 1

    Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 3344, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

  2. 2

    Department 3344, Rigshospitalet, Copenhagen University Hospital, Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen, Denmark

  3. 3

    Aga Khan University Hospital, Department of Medicine, Karachi, Pakistan

  4. 4

    Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 3344, Rigshospitalet, Copenhagen University Hospital, Cochrane Hepato-Biliary Group, Copenhagen, Denmark

*Kate Whitfield, Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 3344, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, Copenhagen, DK-2100, Denmark. kate.whitfield@ctu.rh.dk.

Publication History

  1. Publication Status: New
  2. Published Online: 10 NOV 2010

SEARCH

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To evaluate the beneficial and harmful effects of levamisole for patients with chronic hepatitis B.